ArticleBritish journal of cancer2012

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.

J Cummings et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.